Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.42 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | CDC25B | P30305 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | S100A4 | P26447 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | APAF1 | O14727 | 1/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7650604 | 0.88 | MAOA (0.48) | MAOAMAOBCYP2A6CES1MEN1 | |
| SCHEMBL1450361 | 0.77 | MEN1 (0.38) | MAOAMAOBCYP2A6CES1MEN1 | |
| SCHEMBL2285719 | 0.74 | CES1 (0.41) | MAOAMAOBCYP2A6CES1NPC1 | |
| SCHEMBL1149169 | 0.74 | — | — | |
| SCHEMBL1593140 | 0.71 | MAOA (0.45) | MAOAMAOBCES1MEN1KMT2A | |
| SCHEMBL855431 | 0.70 | MAOA (0.56) | MAOAMAOBCYP2A6CES1MEN1 | |
| SCHEMBL29385474 | 0.70 | MAOA (0.56) | MAOAMAOBCYP2A6CES1MEN1 | |
| SCHEMBL1438260 | 0.68 | CA12 (0.36) | MAOAMAOBCYP2A6CES1MEN1 | |
| Water SCHEMBL460840 | 0.68 | MAOA (0.54) | MAOAMAOBCYP2A6CES1MEN1 | |
| SCHEMBL21267 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099800-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | Pharmacopeia, LLC (US) | 2009-09-16 | — | — | EP | claimed |
| WO-2008060301-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA , LLC (US) | 2008-05-22 | — | — | WO | claimed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | claimed |
| EP-1874772-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-01-09 | — | — | EP | claimed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | claimed |
| WO-2006108103-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2006-10-12 | — | — | WO | claimed |
| CN-101913973-B | Preparation and use of alkylating agents | QUEENS MEDICAL CT | 2013-11-20 | — | — | CN | disclosed |
| US-8551445-B2 | Preparation and use of alkylating agents | THE QUEEN'S MEDICAL CENTER (US) | 2013-10-08 | — | — | US | disclosed |
| US-8554373-B2 | Preparation and use of alkylating agents | THE QUEEN'S MEDICAL CENTER (US) | 2013-10-08 | — | — | US | disclosed |
| EP-1658263-B9 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2011-11-09 | — | — | EP | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-20110028725-A1 | Preparation and Use of Alkylating Agents | THE QUEEN'S MEDICAL CENTER (US) | 2011-02-03 | — | — | US | disclosed |
| CN-101913973-A | Preparation and use of alkylating agents | QUEENS MEDICAL CT | 2010-12-15 | — | — | CN | disclosed |
| US-6030946-A | FUNCTIONS REVERSIBLY, RESULTING IN TIGHT BINDING (LOW DISSOCIATION CONSTANTS) BETWEEN INHIBITOR AND TARGET ENZYME; USED TO TREAT VARIETY OF DISEAES, INCLUDING ARTHRITIS, MUSCULAR DYSTROPHY, INFLAMMATION, TUMOR INVASION, MALERIA | AXYS PHARMACEUTICALS, INC. (US) | 2000-02-29 | — | — | US | disclosed |
| US-5776718-A | Reversible protease inhibitors | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0832099-A1 | REVERSIBLE CYSTEINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0817778-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996040737-A1 | REVERSIBLE CYSTEINE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996030353-A1 | REVERSIBLE PROTEASE INHIBITORS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-10-03 | — | — | WO | disclosed |
| US-4041070-A | ANIMAL GROWTH PROMOTERS, ENHANCING FEED EFFICIENCY | AMERICAN CYANAMID COMPANY (US) | 1977-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | P2RX7, P2RX5, P2RY1 | MAOA 1147/4885MAOB 800/4885CYP2A6 1316/4885 |
| US-20110028725-A1 | Preparation and Use of Alkylating Agents | MGMT, MCL1, TOP2A | MAOA 4058/4885MAOB 3254/4885CYP2A6 2880/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | MAOA 1365/4885MAOB 943/4885CYP2A6 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.